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Summary
Background.  —  In  primary  percutaneous  coronary  intervention  (pPCI),  conﬂicting  data  exist  on
the relative  importance  of  patient  presentation  time  (time  from  symptom  onset  (SO)  to  ﬁrst
medical  contact  [FMC])  and  transfer  time  (time  from  FMC  to  sheath  insertion).Transfer  Time Objectives.  —  To  evaluate  the  impact  of  transfer  time  on  mortality  in  an  unselected  ST-elevation
myocardial  infarction  (STEMI)  population  treated  with  pPCI.
Methods.  —  In  a  well-organized  urban  network,  using  mobile  intensive  care  units  (MICU)  when-
ever possible,  the  impact  of  transfer  time  on  inhospital  mortality  was  evaluated  in  703
unselected consecutive  STEMI  patients  transferred  for  pPCI.
Abbreviations: D2B, door-to-balloon time; ED, emergency department; FMC, ﬁrst medical contact; IQR, interquartile range; MICU,
mobile intensive care unit; PCI, percutaneous coronary intervention; pPCI, primary PCI; SO, symptom onset; STEMI, ST-segment elevation
myocardial infarction; TIMI, thrombolysis in myocardial infarction.
∗ Corresponding author. Bureau 236, Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47-83 boulevard de l’Hôpital, 75013 Paris.
E-mail addresses: gilles.montalescot@psl.aphp.fr, sissel.paulsrud@psl.aphp.fr (G. Montalescot).
1875-2136/$ — see front matter © 2012 Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.acvd.2012.07.007
640  J.  Silvain  et  al.
Results.  —  Our  STEMI  population  included  patients  with  cardiogenic  shock  (5.3%)  and  out-of-
hospital cardiac  arrest  (3.7%).  Longer  transfer  times  were  found  to  be  associated  with  a  stepwise
increase in  mortality  ranging  from  2.99%  in  the  ﬁrst  quartile  (Q1)  up  to  8.65%  in  the  fourth
quartile (Q4)  (P  =  0.005).  This  result  was  noted  in  patients  presenting  early  (≤  2  h  of  SO,  0.96%
for Q1  vs.  9.8%  for  Q4,  P  =  0.006)  but  not  in  late  presenters  (>  2  h  of  SO,  7.00%  for  Q1  vs.  7.8%
for Q4,  P  =  0.85).  After  adjustment  for  confounding  variables  such  as  the  severity  of  patients,
the relationship  between  mortality  and  transfer  time  was  no  longer  apparent.
Conclusions.  —  In  a  well-organized  urban  network  dedicated  to  pPCI,  including  unselected  STEMI
patients, transfer  time  does  not  appear  to  be  a  major  contributor  to  mortality.  The  relationship
of transfer  time  to  mortality  seems  to  be  dependent  on  presentation  time  and  patients’  clinical
severity.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Il  existe  peu  de  données  sur  l’importance  pronostique  relative  du  délai  de  présenta-
tion du  patient  (début  des  symptômes  [DS]  —  premier  contact  médical)  et  du  temps  de  transfert
(premier  contact  médical-insertion  du  désilet)  dans  le  SCA  ST+  traité  par  angioplastie  primaire
(AP).
Objectif. —  Évaluer  l’impact  indépendant  du  temps  de  transfert  sur  la  mortalité  intrahospital-
ière dans  le  SCA  ST+  traité  par  AP.
Matériel  et  méthodes.  —  Dans  un  réseau  urbain  organisé  utilisant  le  SAMU,  l’impact  du  temps
de transfert  sur  la  mortalité  intrahospitalière  a  été  évalué  chez  703  patients  SCA  ST+  non
sélectionnés  transférés  pour  AP.
Résultats.  —  La  population  de  l’étude  comprenait  des  chocs  cardiogéniques  (5,3  %)  et  des  arrêts
cardiaques  extrahospitaliers  (3,7  %).  L’allongement  du  temps  de  transfert  était  associé  à  une
augmentation  progressive  de  la  mortalité  (2,99  %  pour  le  premier  quartile  [Q1]  jusqu’à  8,65  %
pour le  quatrième  quartile  [Q4];  p  =  0,005).  Cette  relation  était  encore  plus  marquée  chez  les
patients se  présentant  précocement  (≤  2  h  du  DS,  0,96  %  pour  Q1  vs  9,8  %  pour  Q4;  p  =  0,006),
mais non  signiﬁcative  pour  les  patients  se  présentant  tardivement  (>  2  h  du  DS,  7,00  %  pour  Q1  vs
7,8 %  pour  Q4;  p  =  0,85).  En  analyse  multivariée,  le  temps  de  transfert  n’était  plus  associé  à  la
mortalité.
Conclusion.  — Dans  un  réseau  urbain  organisé  dédié  à  l’AP,  le  temps  de  transfert  ne  semble
pas être  un  déterminant  majeur  de  la  mortalité.  La  relation  entre  le  temps  de  transfert  et  la
mortalité  précoce  apparaît  fortement  dépendante  du  délai  de  présentation  et  de  la  sévérité
clinique.
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ackground
uropean  and  American  guidelines  support  primary  percu-
aneous  coronary  intervention  (pPCI)  as  the  treatment  of
hoice  for  patients  with  acute  ST-segment  elevation  myocar-
ial  infarction  (STEMI),  especially  when  delivered  within
2  hours  of  symptom  onset  (SO)  [1,2]. Despite  guidelines
nd  quality  improvement  programmes,  reducing  time  to
eperfusion  in  STEMI  patients  remains  important  but  chal-
enging  [3].  Numerous  studies,  including  randomized  trials
nd  meta-analyses,  have  investigated  the  beneﬁts  of  reduc-
ng  ischaemic  time  in  STEMI  patients  treated  with  pPCI.  Most
ave  suggested  a  beneﬁt  in  reducing  time  to  reperfusion
o  salvage  the  myocardium  involved,  subsequently  lowering
he  risk  of  death  [4].  Factors  delaying  time  to  reperfusion  in
PCI  have  been  identiﬁed,  but  vary  according  to  countries,
opulations  and  facilities  of  the  STEMI  networks  involved
5,6].  Moreover,  little  is  known  about  the  importance  of  the
elationship  between  patient  presentation  time  (the  time
rom  SO  to  ﬁrst  medical  contact  [FMC])  and  transfer  time
the  time  from  FMC  to  sheath  insertion).  Field  triage  appears
a
a
as  droits  réservés.
o  be  a  useful  approach  for  reducing  transfer  time  [7]  and
llowing  fast  delivery  of  prehospital  pharmacological  ther-
pies,  thus  potentially  improving  outcomes  after  pPCI  [8].
he  French  Health  Care  System  has  been  using  ﬁeld  triage
ith  mobile  intensive  care  units  (MICUs)  for  a  long  time.
n  on-board  physician,  trained  in  the  diagnosis  of  acute
yocardial  infarction,  triages  the  patients  and  facilitates
apid  transfer  to  a  pPCI  centre  (direct  transfer)  while  at
he  same  time,  administers  prehospital  antiplatelet  therapy
oading  and  anticoagulation.  This  system  is  predominant  in
aris,  with  full  coverage  of  the  city  area  where  pPCI  is  the
xclusive  mode  of  reperfusion  for  STEMI.
While  it  would  seem  logical  that  a  reduction  in  the  time
rom  FMC  to  catheterization  (transfer  time)  would  result
n  improved  mortality  through  reduced  ischaemic  time,  the
ranslation  of  this  general  ﬁnding  in  our  speciﬁc  urban  STEMI
etwork  using  MICUs  routinely  remains  uncertain.  Addition-
lly,  determinants  of  mortality  such  as  presentation  time
re  often  not  considered  in  studies  of  time  delays  for  pPCI
nd  the  most  severe  patients  are  often  excluded  from  such
nalyses.  We  therefore  tested  the  hypothesis  that  transfer
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oImpact  of  transfer  time  on  mortality  in  STEMI  patients  
time  for  pPCI  is  still  a  major  contributor  to  inhospital  death
in  our  speciﬁc  STEMI  network.  For  that  purpose,  we  evalu-
ated  the  independent  impact  of  transfer  time  on  inhospital
mortality  in  unselected  consecutive  STEMI  patients  routinely
treated  with  pPCI  in  a  high-volume  PCI  centre.
Methods
Study design and patient population
Consecutive  patients  admitted  for  pPCI  at  the  catheteriza-
tion  laboratory  of  the  Pitié-Salpêtrière  University  Hospital,
Paris  (France)  between  June  2004  and  February  2007  were
included  in  the  e-PARIS  registry,  a  web-based  registry  used
to  gather  data  from  patients  referred  to  our  institution.
Patients  discharged  without  a  ﬁnal  diagnosis  of  STEMI
were  excluded.  We  identiﬁed  703  patients  with  a  con-
ﬁrmed  STEMI,  including  patients  with  cardiogenic  shock  and
out-of-hospital  cardiac  arrest.  STEMI  was  deﬁned  as  the
presence  of  chest  discomfort  or  symptoms  of  myocardial
ischaemia,  associated  with  new  or  presumed  new  electro-
cardiographic  abnormalities  in  the  ST-segment  (elevation
at  the  J  point  of  at  least  0.2  mV  in  leads  V1,  V2  and  V3
and  at  least  0.1  mV  in  at  least  two  contiguous  leads),  or
new  left  bundle  branch  block,  associated  with  elevation
of  cardiac  enzymes  at  least  three  times  above  the  upper
limit  of  normal.  The  Pitié-Salpêtrière  University  Hospital
is  part  of  the  Paris  STEMI  network,  which  comprises  seven
PCI  centres  that  are  open  24  hours/day,  7  days/week.  Our
centre  and  the  corresponding  MICU  team  cover  the  south
and  east  part  of  the  city,  which  represents  approximately
one-quarter  of  the  Parisian  population.  We  have  on-site
cardiac  surgery  available  and  we  are  the  invasive  hub  for
ﬁve  non-PCI  hospitals,  including  three  emergency  depart-
ments  (EDs)  that  provide  90%  of  the  interhospital  transfer
patients.
First medical contact in the urban
ST-elevation myocardial infarction network
The  FMC  can  be  made  through  two  pathways.  The  ﬁrst  path-
way  is  MICU  contact  (ﬁeld  triage);  the  dispatch  centre  can
be  reached  by  calling  the  dedicated  number  for  medical
emergencies  (‘15’).  All  the  calls  are  operated  by  a  medical
regulator  who  makes  the  decision  to  send  a  fully  equipped
MICU  team  on-site,  with  an  on-board  emergency  doctor  who
is  trained  in  18-lead  ECG  interpretation,  decides  the  reper-
fusion  strategy  and  administers  prehospital  treatment.  The
second  pathway  is  ED  contact,  where  patients  are  triaged  for
pPCI  after  hospital  admission  (‘walk-ins’),  before  ambulance
transfer  to  the  PCI  centre.
Treatment delay deﬁnition
A  total  of  seven  key-time  points  were  identiﬁed  and  sys-
tematically  collected:  SO  or  the  time  of  occurrence  of  the
permanent  ischaemic  symptoms;  FMC  or  time  of  ﬁrst  physi-
cal  medical  contact  with  the  patient  or  performance  of  the
ﬁrst  electrocardiogram;  activation  call  or  ﬁrst  contact  with
the  on-site  pPCI  cardiologist;  catheterization  laboratory
door  time  or  time  of  patient  arrival  to  the  catheterization
S
C
d641
aboratory;  intervention  time  or  arterial  sheath  insertion;
ime  of  ﬁrst  balloon  inﬂation;  time  of  thrombolysis  in
yocardial  infarction  (TIMI)  3  ﬂow  grade.
These  time  points  were  used  to  characterize  two  impor-
ant  time  delays:  presentation  time  (the  time  delay  from
O  to  FMC);  and  transfer  time  (the  time  delay  from  FMC  to
heath  insertion).
Two  additional  time  delays  were  collected  but  not  used
n  the  analysis:  ischaemic  time  (the  time  delay  from  SO  to
ttainment  of  TIMI  3  ﬂow  or  the  end  of  PCI  [only  in  patients
here  TIMI  3  ﬂow  was  obtained]);  and  abciximab  time  (the
ime  delay  from  FMC  to  abciximab  bolus  administration  [only
n  patients  treated  with  abciximab]).
rimary percutaneous coronary intervention
rocedure
ur  catheterization  laboratory  is  open  24  hours/day,  7
ays/week  and  can  be  directly  activated  by  the  ED  or
he  MICU.  Primary  PCI  is  performed  by  the  on-call  senior
nterventional  cardiologist  according  to  contemporary  inter-
entional  guidelines  in  STEMI  presenters.  All  patients
eceived  at  least  aspirin  and  anticoagulation  during  trans-
er.  The  use  of  glycoprotein  IIb/IIIa  inhibitors  was  strongly
ncouraged  for  all  patients  triaged  to  pPCI  and  a  loading
ose  of  clopidogrel  (900  mg)  was  given  as  soon  as  possi-
le,  according  to  our  local  protocol  and  based  on  previous
tudies  [9—11]. Thromboaspiration  was  used  as  often  as
ossible  if  angiographically  indicated,  followed  by  system-
tic  stent  implantation  (unless  considered  inappropriate
y  the  physician).  Subsequent  medical  treatment  included
nti-ischaemic,  lipid-lowering  and  antithrombotic  drugs,
ccording  to  current  treatment  guidelines.
aseline and procedural data
aseline  data  were  prospectively  collected  for  all  patients
nd  entered  in  the  web-based  registry  e-Paris.  Data
egarding  medication  at  admission  and  during  follow-up
ere  recorded,  as  well  as  inhospital  events  until  discharge.
ur  angiographic  core  laboratory  reviewed  all  angiographic
lms  and  blindly  evaluated  TIMI  ﬂow  grade,  TIMI  frame
ount  and  TIMI  myocardial  blush  grade.  Special  atten-
ion  was  given  to  comorbidities  and  a  risk  proﬁle  was
eﬁned  for  each  patient  according  to  the  TIMI  risk  score  for
TEMI  [12].
tudy objectives
ur  main  objective  was  to  evaluate  the  impact  of  transfer
ime  on  inhospital  death,  deﬁned  as  death  from  any  cause
uring  the  initial  hospitalization  period.  Secondary  objec-
ives  were  to  evaluate  the  impact  of  presentation  time  on
ortality,  deﬁning  early  presenters  as  patients  with  an  SO  —
MC  delay  ≤  120  minutes  and  late  presenters  as  those  with  an
O  —  FMC  delay  >  120  minutes.  We  also  evaluated  the  effect
f  ﬁeld  triage  on  the  different  key-time  intervals.tatistical analysis
ontinuous  variables  are  presented  as  means  ±  standard
eviations  and  were  compared  with  Student’s  t  test.
642  J.  Silvain  et  al.
Table  1  Baseline  characteristics  of  the  patients.
Total  (n  =  703)  ED  (n  =  227;  32.3%)  MICU  (n  =  476;  67.7%)  P
Age  (years) 63  ±  14  61.7  ±  15  63.3  ±  14  0.16
Women  154  (21.9)  49  (21.6)  115  (24.2)  0.45
BMI  (kg/m2)  25.6  ±  4  25.3  ±  4  25.7  ±  4  0.22
Obesity  (BMI  >  30  kg/m2)  98  (13.9)  28  (12.3)  70  (14.7)  0.34
Diabetes 144  (20.5)  53  (23.3)  91  (19.1)  0.19
Dyslipidaemia 303  (43.1) 81  (35.7) 232  (48.8) 0.0009
Smoker 302  (43) 94  (41.3) 208  (43.7) 0.53
Hypertension 302  (43) 100  (44) 202  (42.5) 0.41
Family  history  of  CAD  153  (21.7)  48  (21.3)  115  (24.1)  0.32
Previous  MI  101  (14.4)  32  (14.2)  69  (14.5)  0.82
Previous  PCI  90  (12.8)  30  (13.3)  60  (12.5)  0.75
Previous  CABG  20  (3)  7  (3.0)  13  (2.7)  0.84
CrCl  (mL/minute)  81.6  ±  40  82.5  ±  40  81.3  ±  40  0.80
CrCl  <  60  mL/minute  206  (29.3)  71  (31)  145  (30.5)  0.80
Heart  rate  (bpm)  78  ±  18  78  ±  17  77  ±  18  0.92
Systolic  BP  (mmHg)  128  ±  25  128  ±  26  128  ±  24  0.93
Anterior  MI  336  (47.8)  98  (43.2)  228  (47.9)  0.21
Killip  1.3  ±  0.7  1.3  ±  0.7  1.3  ±  0.7  0.91
Killip  class  ≥  2  128  (18.2)  34  (15.2)  94  (19.7)  0.55
Cardiogenic  shock  37  (5.3)  10  (4.5)  27  (5.6)  0.57
Out-of-hospital  cardiac  arrest  26  (3.7)  3  (1.3)  23  (4.9)  0.017
Troponin  I  (peak),  UI/L  77.2  ±  90  66.7  ±  82.9  81  ±  116  0.08
TIMI  risk  score  3.8  ±  2.6  3.9  ±  2.6  3.8  ±  2.6  0.57
TIMI  risk  score  >  4  249  (35.4)  79  (35.0)  170  (35.8)  0.84
Data are mean ± standard deviation or number (%). BMI: body mass index; BP: blood pressure; bpm: beats per minute; CABG: coronary
artery bypass graft; CAD: coronary artery disease; CrCl: creatinine clearance; ED, emergency department; MI: myocardial infarction;
MICU: mobile intensive care unit; PCI: percutaneous coronary intervention; TIMI: thrombolysis in myocardial infarction.
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pategorical  variables  are  expressed  as  rates  or  propor-
ions  and  were  compared  by  the  Chi2 test  or  Fisher’s
xact  test.  According  to  the  American  College  of  Cardiol-
gy/American  Heart  Association  Task  Force  on  Performance
easures  [13], time  intervals  are  expressed  as  means  with
nterquartile  ranges  (IQRs;  25th—75th  percentiles)  and  the
on-parametric  Wilcoxon  rank-sum  test  was  adopted  for
roup  comparisons  (ﬁeld  triage  group  [MICU]  versus  non-
eld  triage  group  [ED])  of  time-delay.  To  address  the
mpact  of  transfer  time  on  inhospital  death  we  divided
he  transfer  time  into  quartiles  and  a  multivariable  logis-
ic  regression  model  was  ﬁt  to  evaluate  the  independent
ariables  associated  with  inhospital  mortality  with  their
djusted  effect  estimates  on  inhospital  mortality.  The
ollowing  variables  (potential  confounders)  that  were  asso-
iated  with  inhospital  mortality  in  the  univariate  analysis
ere  included  in  the  multivariable  model:  age,  creatinine,
moking  status,  high  blood  pressure,  renal  insufﬁciency,
IMI  risk  score  >  4,  out-of-hospital  cardiac  arrest,  heart
ate,  cardiogenic  shock,  troponin  peak,  initial  TIMI  3  ﬂow,
ultivessel  disease,  presentation  time  group  and  ﬁeld
riage.  All  tests  were  two-sided  with  a  signiﬁcance  level
xed  at  5%.  We  undertook  all  analyses  with  SAS  soft-
are,  version  9.0  (SAS  Institute  Inc.,  Cary,  NC,  USA).
he  study  was  approved  by  the  local  scientiﬁc  ethi-
al  committee  (CPP)  at  the  Pitié-Salpêtrière  University
ospital.
p
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Mesults
atient population and baseline characteristics
aseline  characteristics,  treatments  and  procedural  data
or  the  703  patients  included  in  this  study  are  shown  in
ables  1  and  2.  Patients  were  compared  according  to  pre-
ospital  triage,  i.e.  patients  who  were  referred  by  the  MICU
ﬁeld  triage,  n  =  476;  67.7%)  with  direct  transfer  from  the
eld  to  the  catheterization  laboratory  versus  those  referred
y  the  ED  (non-ﬁeld  triage,  n  =  227;  32.3%)  with  inter-  or
ntrahospital  transfer  for  pPCI.  All-comer  STEMI  patients
ere  recruited  with  high-risk  proﬁles  and  frequent  comor-
idities.  Clopidogrel  loading  dose  was  administered  either
n  the  ED  or  during  transfer  by  MICU  and  was  ≥  600  mg  in
ne-third  of  patients.  Clopidogrel  loading  was  completed
n  all  patients  to  reach  a  ﬁnal  loading  dose  of  900  mg
hen  discharged  from  the  catheterization  laboratory  [9,11].
bciximab  was  used  in  73.7%  of  patients  and  enoxaparin
as  the  most  common  anticoagulant  used.  Nine  out  of  10
atients  (88%)  underwent  pPCI  with  radial  access.  MICU
atients  differed  from  ED  patients  with  respect  to  clinical
resentation  and  risk  proﬁle;  for  example,  MICU  patients  dis-
layed  a  much  higher  rate  of  out-of-hospital  cardiac  arrests
4.9%  vs.  1.3%;  P  =  0.017).  Angiographic  success  was  similar
n  both  groups  but  complete  ST  resolution  was  higher  in  the
ICU  group  than  in  the  ED  group  (71%  vs.  64.7%;  P  =  0.027).
Impact  of  transfer  time  on  mortality  in  STEMI  patients  643
Table  2  Treatment  delay  and  treatments.
Total  (n  =  703)  ED  (n  =  227;  32.3%)  MICU  (n  =  476;  67.7%)  P
Presentation  time  (SO—FMC)  110  [51—300]  159  [70—405]  100  [50—240]  0.0002
Transfer  time  (FMC—angiography)  104  [80—155]  150  [92—270]  95  [77—124]  <  0.0001
Ischaemic  time  (SO—TIMI  3)  254  [175—497]  380  [225—752]  225  [160—392]  <  0.0001
Abciximab  time  (FMC—abciximab)  91  [61—148]  140  [88—265]  83  [56—117]  <  0.0001
FMC—activation  call  36  [20—70]  67  [30—156]  33  [20—50]  <  0.0001
Activation  call—cath-lab  door  40  [25—60]  55  [35—75]  35  [25—50]  <  0.0001
Cath-lab  door—angiography  20  [15—31]  20  [10—39]  20  [15—30]  0.92
Angiography—PCI  20  [15—30]  20  [15—30]  20  [15—30]  0.98
Off-hours  admission  425  (60.4)  135  (59.7)  290  (61.2)  0.66
Primary  PCI  659  (93.7)  223  (98.5)  436  (91.6)  0.0001
Thrombolysis  43  (6.1)  3  (1.5)  40  (8.4)  0.0002
Radial  access  619  (88)  198  (87.5)  421  (88.5)  0.70
Multivessel  disease  349  (49.6)  105  (46.3)  244  (51.3)  0.24
Baseline  TIMI  ﬂow  =  3  125  (17.8)  34  (15)  90  (18.9)  0.18
Final  TIMI  ﬂow  =  3  618  (87.9)  195  (86.1)  423  (89.0)  0.27
LVEF  (%)  50  ±  11  50  ±  11  50  ±  12  0.9
ST  resolution  >  70%  (486)  69.1  (147)  64.7  (338)  71  0.027
Abciximab  before  PCI  105  (14.9)  25  (11)  80  (16.7)  0.047
Abciximab,  cath-lab  500  (71.1)  158  (69.5)  342  (71.9)  0.51
Abciximab,  all  518  (73.7)  170  (74.8)  348  (73.1)  0.6
Clopidogrel  before  PCI  (LD  600  or  900  mg)  223  (31.7)  83  (36.7)  150  (31.6)  0.17
Clopidogrel  LD  (ﬁrst  24  hours)  674  (95.8)  220  (97.3)  454  (95.3)  0.37
Aspirin  after  PCI  654  (93)  214  (94.4)  440  (92.4)  0.3
IV  inotropic  drugs  114  (16.2)  30  (13.2)  84  (17.7)  0.13
IABP  46  (6.5)  13  (5.9)  33  (7)  0.6
UFH  266  (37.8)  45  (20.0)  221  (46.5)  <  0.0001
LWMH  462  (65.7)  167  (73.6)  295  (62)  0.002
Length  of  stay  in  ICU  3.9  ±  3.8  3.5  ±  4.4  4.2  ±  3.6  0.02
Beta-blockers  569  (80.9)  181  (79.6)  388  (81.6)  0.52
ACE  inhibitors/ARBs  572  (81.4)  179  (79.1)  393  (82.6)  0.26
Statins 645  (91.7)  212  (93.6)  433  (90.9)  0.2
Data are mean ± standard deviation, median (interquartile range) or number (%). ACE: angiotensin-converting enzyme; ARBs: angiotensin-
receptor blockers; cath-lab: catheterization laboratory; ED: emergency department; FMC: ﬁrst medical contact; IABP: intra-aortic
balloon pump counterpulsion; ICU: intensive care unit; IV: intravenous; LD: loading dose; LMWH: low-molecular-weight heparin; LVEF:
left ventricular ejection fraction; MICU: mobile intensive care unit; PCI: percutaneous coronary intervention; SO: symptom onset; TIMI:
thrombolysis in myocardial infarction; UFH: unfractionated heparin.
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The  inhospital  mortality  rate  was  high  in  the  overall  study
population  and  did  not  differ  according  to  prehospital  triage
(6.0%  for  the  MICU  group  vs.  5.4%  for  the  ED  group;  P  =  0.7).
Early  presenters  demonstrated  a  trend  towards  lower  inhos-
pital  mortality  compared  with  late  presenters  (4.5%  vs.  6.5%;
P  =  0.24).  Major  independent  predictors  of  inhospital  mor-
tality  are  presented  in  Table  3  and  are  mainly  related  to
the  severity  of  both  the  underlying  CAD  and  the  myocardial
infarction  presentation.  The  use  of  enoxaparin  (over  unfrac-
tionated  heparin)  and  the  radial  approach  were  independent
predictors  of  better  survival.
We  performed  a  sensitivity  analysis  in  the  subgroup  of
patients  presenting  within  2  hours  after  SO  (370  patients),
which  conﬁrmed  the  ﬁndings  of  the  analysis  in  the  global
group,  although  the  model  lacked  power  to  demonstrate
signiﬁcant  effects  of  Killip  class  >  2,  multivessel  disease  and
enoxaparin  treatment.
M
i
tUnadjusted  analysis  of  the  impact  of  transfer  time  on
ortality  showed  a  clear  stepwise  increase  in  inhospital
ortality  with  respect  to  quartile  of  transfer  time,  ranging
rom  2.99%  in  the  ﬁrst  quartile  (Q1)  up  to  8.65%  in  the  fourth
uartile  (Q4)  (P  =  0.005)  (Table  4).  The  impact  of  transfer
ime  on  mortality  was  only  present  in  early  presenters  (0.96%
or  Q1  vs.  9.8%  for  Q4;  P  =  0.006)  while  no  signiﬁcant  rela-
ionship  was  observed  in  late  presenters  (7.00%  for  Q1  vs.
.8%  for  Q4;  P  =  0.85)  (Fig.  1).  In  the  multivariable  analysis
djusted  for  patients’  baseline  characteristics,  risk  factors
or  mortality  and  time  of  presentation,  there  was  no  longer
n  association  between  transfer  time  and  mortality.
mpact of ﬁeld triage by mobile intensive care
nits on treatment delaysedians  of  presentation  time  and  transfer  time  were  shorter
n  MICU  versus  ED  patients  by  55  and  59  minutes,  respec-
ively  (Fig.  2).  MICU  usage  was  a  strong  predictor  of  reduced
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Table  3  Independent  predictors  of  inhospital  mortality  in  the  total  population  and  in  patients  presenting  early
(in  ≤  2  hours  of  symptom  onset).
Adjusted  ORa 95%  CI  P
All  patients
EF <  30% 9.40 3.66—24.18  <  0.0001
Cardiogenic  shock 5.41 2.08—22.97  0.0005
Killip  class  ≥  2  4.04  2.2—7.25  <  0.0001
Out-of-hospital  cardiac  arrest  3.3  1.27—9.0  0.017
Multivessel  disease  2.46  1.16—5.20  0.02
Age  (per  10  years)  1.98  1.49—2.61  <  0.001
Enoxaparin  use  0.23  0.10—0.53  0.0006
Radial  PCI  0.19  0.08—0.44  <  0.0001
Early  presenters  (in  ≤  2  hours  of  SO) 0.92 0.41—2.07  0.85
Patients  presenting  earlyb
Cardiogenic  shock  60.5  2.5—503  0.02
EF  <  30%  36.9  3.24—62.2  0.005
Out-of-hospital  cardiac  arrest  15.7  1.13—304  0.04
Multivessel  disease  1.75  0.22—17.5  0.59
Age  (per  10  years)  1.17  1.06—1.36  0.007
Killip  class  ≥  2  0.6  0.02—8.34  0.7
Enoxaparin  use  0.53  0.06—4.1  0.5
Radial  PCI  0.04  0.004—0.33  0.004
CI: conﬁdence interval; EF: ejection fraction; OR: odds ratio; PCI: percutaneous coronary intervention; SO: symptom onset; TIMI:
thrombolysis in myocardial infarction.
a Adjustment variables were predictors of mortality in the univariate analysis (age, creatinine, smoking status, high blood pressure,
renal insufﬁciency, TIMI risk score > 4, out-of-hospital cardiac arrest, heart rate, cardiogenic shock, troponin peak, initial TIMI 3 ﬂow,
multivessel disease and presentation time).
b Presentation time was not included in the multivariable model for patients presenting early.
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aransfer  time  (t  value  7.75;  P  <  0.0001)  in  a  dedicated  mul-
ivariable  analysis.  The  time  delay  from  catheterization
aboratory  door  to  sheath  insertion  or  ﬁrst  balloon  inﬂation
id  not  differ  between  MICU  and  ED  patients.  Field  triage
y  MICU  resulted  in  a  signiﬁcantly  reduced  median  time  to
Table  4  Inﬂuence  of  transfer  time  on  inhospital
mortality.
Transfer  time
(minutes)
OR 95%  CI  P
Unadjusted  0.005
Q1  ≤  80  1
Q2  81—104  2.08  0.67—6.49
Q3  105—155  2.84  0.98—8.22
Q4  ≥  156  4.00  1.43—11.17
Adjusteda 0.41
Q1  ≤  80  1
Q2  81—104  2.13  0.50—8.98
Q3  105—155  1.99  0.54—7.32
Q4  ≥  156  1.94  0.51—7.33
CI: conﬁdence interval; OR: odds ratio.
a Adjustment variables were predictors of mortality in the uni-
variate analysis (age, creatinine, smoking status, high blood
pressure, renal insufﬁciency, TIMI risk score > 4, out-of-hospital
cardiac arrest, heart rate, cardiogenic shock, troponin peak,
initial TIMI 3 ﬂow, multivessel disease and presentation time).
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administration  of  abciximab  (by  57  minutes)  in  comparison
ith  ED  patients.
Median  presentation  time  for  the  whole  study  popula-
ion  was  110  minutes  (IQR,  51—300)  and  was  57  minutes
IQR,  30—90)  in  early  presenters  (FMC  within  2  hours  of
O,  n  =  357)  versus  324  minutes  (IQR,  195—693)  in-late  pre-
enters  (FMC  >  2  hours  of  SO,  n  =  349).  Conversely,  median
ransfer  time  was  shorter  in  early  presenters  compared  with
n-late  presenters  (95  minutes  [IQR,  76—129]  vs.  117  minutes
IQR,  85—196];  P  <  0.0001).  The  more  rapid  transfer  in  early
resenters  is  explained  by  a  higher  rate  of  ﬁeld  triage  by
ICU  in  early  presenters  who  seem  to  call  MICU  more  fre-
uently  than  late  presenters  who  prefer  to  ‘walk-in’  to  the
D  (73.4%  vs.  62.9%).
iscussion
n  the  present  work,  we  aimed  to  evaluate  the  indepen-
ent  effect  of  transfer  time  on  inhospital  mortality  of  STEMI
atients  treated  with  pPCI  in  a  well-organized  urban  STEMI
etwork  using  ﬁeld  triage  with  MICU  routinely.
After  univariate  analysis,  we  found  that  a reduction  in
ransfer  time  for  pPCI  is  associated  with  improved  outcomes,
n  effect  that  is  only  present  in  early  presenters  (<  2  hours
f  SO)  supporting  the  hypothesis  of  a threshold  effect  in
ime  delays  (ischaemic  time)  beyond  which  rapid  treatment
oes  not  further  improve  mortality  [14]. However,  after
djustment  for  baseline  characteristics,  including  clinical
Impact  of  transfer  time  on  mortality  in  STEMI  patients  
Figure 1.
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resentation  and  time  from  SO  to  FMC,  there  was  no  longer
 relationship  between  transfer  time  and  hospital  mortality,
uggesting  that  individual  patient  risk  and  time  to  presen-
ation  are  major  confounding  factors  when  analysing  the
mpact  of  reperfusion  delay  on  mortality.  Our  data  sup-
orts  the  idea  that  factors  other  than  transfer  time  are
ey  determinants  of  inhospital  mortality,  such  as  the  use
f  enoxaparin  rather  than  unfractionated  heparin  as  the
nticoagulation  regimen  or  the  use  of  the  radial  approach,
oth  of  which  are  independently  associated  with  better  out-
omes.  Finally,  we  demonstrate  that  a  regional  organization
ased  on  ﬁeld  triage  by  MICU  with  wide  coverage  of  the  city
nd  rapid  transfer  to  the  catheterization  laboratory  is  very
ffective  for  diminishing  transfer  time  in  patients  presenting
ith  chest  pain.
It  is  only  recently  that  studies  have  pointed  out  that
echanical  reperfusion  strategies  should  recognize  the
mportance  of  the  presentation  time  delay  [15]. Atten-
ion  also  needs  to  be  given  to  patient  characteristics,  as
emonstrated  in  a  previous  study  where  door-to-balloon
D2B)  time  did  impact  late  survival  in  high-risk  and  early
resenters  but  not  in  low-risk  patients  or  late  presen-
ers  [16]. Although  better  triage  to  improve  early  outcome
f  STEMI  presenters  is  now  established,  recent  guidelines
ay  little  tribute  to  patient  characteristics  and  clinical
resentation  in  the  process  of  decision  making  regarding
he  best  reperfusion  strategy  [2].  Our  results  suggest
hat  presentation  time  and  patient  baseline  characteristics
re  the  most  relevant  factors  impacting  early  mortal-
ty.  Indeed,  the  dramatic  reduction  in  transfer  time  for
PCI  by  using  MICU  to  treat  earlier  and  triage  patients  in
he  ﬁeld  had  no  signiﬁcant  impact  on  inhospital  mortal-
ty.
Our  results  do  not  refute  the  concept  of  ‘time  is  muscle’
ut  rather  reﬂect  the  complexity  of  identifying  independent
eterminants  of  mortality  in  STEMI  presenters.  Not  only  do
hey  highlight  the  importance  of  patient  mortality  risk  in  the
etting  of  pPCI,  such  as  patient  risk  factors,  infarct  severity
17]  and  symptom  duration  [18]  —  key  determinants  of  early
ortality  in  our  series  —  but  they  also  draw  attention  to
he  relative  importance  of  factors  other  than  transfer  time.
ndeed,  in  our  study,  presentation  time  represents  half  of  the
otal  ischaemic  time,  itself  a  major  contributor  to  mortality
19].  Our  ﬁndings  are  in  accordance  with  a  recent  analysis
f  time  delay  in  randomized  trials  by  Brodie  et  al.,  which
emonstrated  that  lowering  time  to  treatment  (D2B  time  in
his  study)  results  in  improved  prognosis  in  early  presenters
nly  [20].
Importantly,  when  using  MICU  for  ﬁeld  triage,  we  found
hat  time  to  treatment  could  be  dramatically  reduced,
ith  shorter  presentation  and  transfer  times  observed.  Sim-lar  reductions  were  seen  in  another  recent  study  [21],
einforcing  the  need  to  favour  this  pathway  that  facilitates
oth  direct  transfer  to  a  pPCI  centre  and  fast  administration
igure 1. Inhospital mortality according to quartiles of transfer
ime (symptom onset — angiography) (above) and divided accord-
ng to the group of presentation (below). The early presenters
symptom onset — ﬁrst medical contact ≤ 2 hours) group is on
he left and the late presenters (symptom onset — ﬁrst medical
ontact > 2 hours) group is on the right. ns: not signiﬁcant.
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migure 2. Median time delay depending on type of ﬁrst medica
below). PCI: percutaneous coronary intervention; TIMI: thrombolys
f  antithrombotic  therapy,  two  strategies  known  to  be  asso-
iated  with  better  outcomes  [9,10,22—24]. MICU  usage  did
ot  appear  to  impact  the  prognosis  of  our  study  population.
hese  controversial  ﬁndings  may  be  explained  by  the  fact
hat  the  MICU  was  more  frequently  the  FMC  for  the  sickest
atients  with  a  higher  rate  of  out-of-hospital  cardiac  arrest
nd  cardiogenic  shock,  and  who  were  unable  to  ‘walk-in’  to
he  ED.
Since  the  launch  of  the  American  College  of  Cardiol-
gy’s  D2B  Alliance  and  the  American  Heart  Association’s
ission:  lifeline  programmes,  the  focus  is  now  on  systems
mprovement  of  reperfusion  in  patients  with  STEMI.  With
n  average  median  transfer  time  of  104  minutes,  our  study
hows  that  even  in  a  well-organized  urban  STEMI  network,
urther  efforts  can  be  made  to  improve  transfer  time.  This
elay  is  mainly  driven  by  long  interhospital  transfer  between
D  and  PCI  centres,  as  highlighted  by  a  two-fold  reduction  in
ransfer  time  with  ﬁeld  triage  and  direct  transfer  by  MICU.
ur  data  will  serve  as  feedback  to  all  the  participants  in  our
TEMI  network  to  highlight  the  necessity  of  improvement  in
ur  time  delays  in  the  setting  of  pPCI  as  an  exclusive  mode  of
eperfusion;  otherwise,  thrombolysis  may  become  an  option
or  early  presenters  with  long  transfer  delays.
We  acknowledge  several  limitations  to  this  study.  It  rep-
esents  the  results  of  a  single-centre  registry  with  several
r
v
a
Etact: mobile intensive care unit (above); emergency department
myocardial infarction.
election  biases,  even  if  our  organization  network  covers  a
arge  geographical  area.  We  have  considered  transfer  time
from  electrocardiogram  to  sheath  insertion)  instead  of  the
2B  time  to  evaluate  the  impact  of  physician-related  time  on
ortality.  The  D2B  time  is  controversial  in  our  hub  organiza-
ion.  Indeed,  the  concept  of  ‘hospital  door’  is  questionable
n  a  prehospital  system  that  bypasses  the  emergency  room.
oreover,  the  ‘balloon’  time  is  also  questionable  as  it  does
ot  correspond  to  effective  reperfusion  (deﬁnite  TIMI  3  ﬂow)
nd  is  biased  by  long  procedures  that  are  rare  but  associ-
ted  with  delayed  reperfusion  or  procedures  without  balloon
nﬂation  (e.g.  thromboaspiration  only).  Sheath  insertion  cor-
esponds  to  the  beginning  of  the  angiography  and  is  an
nbiased  time  point.  In  addition,  we  did  not  use  ischaemic
ime  in  our  analysis  because  a  substantial  percentage  of
atients  never  achieved  TIMI  3  ﬂow  in  this  real-life  study.
Concerning  the  observed  positive  effect  of  the  radial
pproach  on  mortality,  the  femoral  approach  is  predomi-
antly  used  in  the  most  severe  patients  in  cardiogenic  shock
nd  although  we  adjusted  our  results  on  the  basis  of  a
ultivariable  model  that  included  patient’s  severity,  theseesults  should  still  be  considered  with  caution.  Our  data  pro-
ide  the  experience  of  an  urban  STEMI  network  using  MICU
nd  a  single  high-volume  centre  dedicated  to  radial  pPCI.
ven  if  it  might  reﬂect  current  practice  in  other  similar
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high-volume  centres  performing  expedited  care  for  STEMI
patients,  we  acknowledge  that  our  conclusions  may  not  be
fully  extrapolated  to  other  centres  with  a  different  prac-
tice.  Nevertheless,  two  recent  trials  [25,26]  conﬁrmed  our
data  and  demonstrated  fewer  vascular  complications  and
major  cardiovascular  and  cerebral  events  with  the  transra-
dial  approach  compared  with  the  transfemoral  approach  in
an  acute  coronary  syndrome  population.
In  conclusion,  our  present  investigation  has  several
major  implications.  First,  it  highlights  that  the  association
between  transfer  time  and  early  mortality  of  STEMI  patients
treated  with  pPCI  is  strongly  dependent  on  baseline  char-
acteristics  and  clinical  presentation.  Next,  it  demonstrates
that  reduction  in  the  total  ischaemic  time  can  be  achieved
by  ﬁeld  triage  using  MICU,  allowing  fast  delivery  of  appro-
priate  care  to  the  sickest  patients.  It  also  emphasizes  the
need  to  focus  on  important  prognostic  factors  other  than
just  transfer  time,  such  as  the  use  of  the  radial  approach  —
an  easy-to-apply  technique  with  a  potentially  high  beneﬁt  in
bleeding  reduction  [27]  — and  the  use  of  enoxaparin,  which
showed  better  prognosis  over  unfractionated  heparin  in  a
registry  [28]  and  was  conﬁrmed  in  the  randomized  ATOLL
trial  [29].
Finally,  the  ultimate  goal  should  be  a  reduction  in
the  overall  ischaemic  time,  that  comprises  patient-related
delays  (time  to  call),  presentation  time  (SO  — FMC  time)  and
time  to  treatment  (transfer  time  or  D2B).  Such  efforts  would
require  a  multifaceted  approach,  involving  patient  educa-
tion,  global  communication  from  the  public  health  system
to  the  population  and  appropriate  changes  in  the  medical
management  of  STEMI  treated  with  pPCI.
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